The global Minimal Residual Disease Market was valued at USD 2.53 billion in 2024 and is projected to reach USD 9.16 billion by 2034, exhibiting a CAGR of 13.7% during the forecast period. The market is being fueled by rising prevalence of hematologic malignancies, technological advancements in molecular diagnostics, and increasing adoption...
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek